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CLINICAL EXPERIENCE WITH THE EFFECT OF ORAL 8-METHOXY-
PSORALEN ON THE PIGMENTARY RESPONSES
OF THE SKIN TO STJNLIGHT*
NORMAN B. KANOF, M.D., Med.Se.D.
8-methoxypsoralen can sometimes induce
melanin repigmentation in vitiliginous skin.
Since this fact was first formally reported by
El Mofty (1) in 1952, many investigators have
observed the effect of methoxsalen on the re-
sponses of "normal" and diseased skin to sun-
light. It was soon reported (2, 3) that topical
application of 8-methoxypsoralen prior to sun
exposure would increase the pigmentation of
"normal" skin. Many of us who were studying
this drug and its effects in vitiligo also noted
that its oral use seemed to intensify the
pigmentary response of normal skin to sun ex-
posure. This action was discussed informally
many times before it was reported in the litera-
ture in 1955 (4, 5).
Since 1952, I have had the opportunity to
observe the effect on the skin's responses to
sunlight of methoxsalen administered orally in
more than 200 persons. This number includes
patients with and without vitiligo, in clinic and
private practice.
Methoxsalen was taken in doses of ten or
twenty milligrams one to two hours prior to
sun exposure once or twice daily. The maximum
daily dose of the psoralen was 40 mg. Many
patients took this drug for many months without
interruption. Because some early reports implied
that toxic reactions to methoxsalen might occur,
urinalyses, blood counts and liver function tests
were performed at regular intervals on many of
these persons. We did not observe any evidence
of liver damage or any effect on the blood or
urine from 8-methoxypsoralen in any of our
patients. An occasional patient complained of
some gastrointestinal distress, but it was never
necessary to discontinue therapy because of
this.
The amount of sun exposure which should
follow the administration of methoxsalen was
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difficult to standardize because of the wide range
of individual tolerance. The chemical augments
all of the skin's responses to sunlight, the un-
wanted inflammatory ones as well as the sought-
after pigmentation. It is necessary to stress the
fact that methoxsalen does not allow limitless
sun exposure without burning (which many
patients assume). Our rule of thumb was to
allow initially such sun exposure as the patient
knew, from past experience, his skin could
tolerate without burning. The length of exposure
could then be increased as hyperpigmentation
and especially as thickening of the horny layer
occurred.
When methoxsalen and sunlight exposure were
combined in this manner, distinct intensification
of the tanning response beyond that to be ex-
pected from a similar exposure to sunlight
without preceding 8-methoxypsoralen occurred
in about 75 per cent of the patients. Little or no
augmentation of tanning occurred in the re-
maining 25 per cent. Redness and some mild
discomfort of the exposed areas did occasionally
occur but severe inflammatory effects were not
seen unless there was gross overexposure to
sunlight before hyperpigmentation had appeared.
sUMMARy
8-methoxypsoralen taken by mouth prior to
sun exposure augments the skin responses to
sunlight.
By careful attention to the dose of the drug
and to the amount of subsequent sun exposure,
it is possible, in many persons, greatly to accen-
tuate the skin's pigmentary responses to sunlight
with little or no increase in the skin's inflamma-
tory response.
We have seen no toxic effects from the oral
administration of methoxsalen in doses up to 40
mg. daily for many months.
Carefully controlled investigative procedures
are necessary to determine the safest and most
efficient method to use methoxsalen for sun
tanning.
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